BMP2/7 heterodimer can modulate all cellular events of the in vitro RANKL-mediated osteoclastogenesis, respectively, in different dose patterns

Tissue Engineering - Part A

Volumn 18, Issue 5-6, 2012, Pages 621-627

  Zheng, Yuanna ^a,b,c   Wang, Linhong ^d   Zhang, Xiaodan ^b   Zhang, Xin ^b   Gu, Zhiyuan ^a,b   Wu, Gang ^c  

^a ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d ZHEJIANG PROVINCIAL PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CALCIUM PHOSPHATE; CELL CULTURE; CELL PROLIFERATION; GENE EXPRESSION; TISSUE ENGINEERING;

BONE MORPHOGENETIC PROTEINS; BONE REGENERATION; CELL LINES; CELLULAR EVENTS; CONCENTRATION PATTERNS; COUPLING PROCESS; DOSE-DEPENDENT; DOSE-DEPENDENT MANNER; FUNCTIONAL CHARACTERISTICS; GENES EXPRESSION; HETERODIMERS; HOMODIMERS; IN-VITRO; LOW CONCENTRATIONS; MORPHOLOGICAL CHARACTERISTIC; NUCLEAR FACTORS; OSTEOCLASTOGENESIS; RECEPTOR ACTIVATOR;

BIOMOLECULES;

BMP2 PROTEIN, MOUSE; BMP7 PROTEIN, MOUSE; BONE MORPHOGENETIC PROTEIN 2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOGENIC PROTEIN 1; TNFSF11 PROTEIN, MOUSE;

ANIMAL; ARTICLE; BONE REMODELING; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CYTOLOGY; DOSE RESPONSE; DRUG EFFECT; GENE EXPRESSION REGULATION; METABOLISM; MOUSE; OSTEOCLAST; PROTEIN MULTIMERIZATION; TISSUE ENGINEERING;

ANIMALS; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 7; BONE REMODELING; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION; MICE; OSTEOCLASTS; PROTEIN MULTIMERIZATION; RANK LIGAND; TISSUE ENGINEERING;

EID: 84857869168     PISSN: 19373341     EISSN: 1937335X     Source Type: Journal    
DOI: 10.1089/ten.tea.2011.0366     Document Type: Article

References (52)

1. Carson, J.S., and Bostrom, M.P. Synthetic bone scaffolds and fracture repair. Injury 38 Suppl 1, S33, 2007.
2. Haman, J.D., Scripa, R.N., Rigsbee, J.M., and Lucas, L.C. Production of thin calcium phosphate coatings from glass source materials. J Mater Sci Mater Med 13, 175, 2002.
3. Saito, N., and Takaoka, K. New synthetic biodegradable polymers as BMP carriers for bone tissue engineering. Biomaterials 24, 2287, 2003.
4. Liu, Y., de Groot, K., and Hunziker, EB. BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. Bone 36, 745, 2005.
5. Liu, Y., Huse, R.O., de Groot, K., Buser, D., and Hunziker, E.B. Delivery mode and efficacy of BMP-2 in association with implants. J Dent Res 86, 84, 2007.
6. Takahashi, Y., Yamamoto, M., and Tabata, Y. Enhanced osteoinduction by controlled release of bone morphogenetic protein-2 from biodegradable sponge composed of gelatin and beta-tricalcium phosphate. Biomaterials 26, 4856, 2005.
7. Jeon, O., Song, S.J., Kang, S.W., Putnam, A.J., and Kim, B.S. Enhancement of ectopic bone formation by bone morphogenetic protein-2 released from a heparin-conjugated poly(Llactic-co-glycolic acid) scaffold. Biomaterials 28, 2763, 2007.
8. Urist, M.R., and Strates, B.S. Bone morphogenetic protein. J Dent Res 50, 1392, 1971.
9. Cheng, H., Jiang, W., Phillips, F.M., Haydon, R.C., Peng, Y., Zhou, L., et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am 85-A, 1544, 2003.
10. Chen, D., Zhao, M., and Mundy, G.R. Bone morphogenetic proteins. Growth Factors 22, 233, 2004.
11. Boden, S.D., Kang, J., Sandhu, H., and Heller, J.G. Use of recombinant human bone morphogenetic protein-2 to achieve posterolateral lumbar spine fusion in humans: a prospective, randomized clinical pilot trial: 2002 Volvo Award in clinical studies. Spine 27, 2662, 2002.
12. Govender, S., Csimma, C., Genant, H.K., Valentin-Opran, A., Amit, Y., Arbel, R., et al. Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84-A, 2123, 2002.
13. Toth, J.M., Boden, S.D., Burkus, J.K., Badura, J.M., Peckham, S.M., and McKay, W.F. Short-term osteoclastic activity induced by locally high concentrations of recombinant human bone morphogenetic protein-2 in a cancellous bone environment. Spine (Phila Pa 1976) 34, 539, 2009.
14. Zhu, W., Kim, J., Cheng, C., Rawlins, B.A., Boachie-Adjei, O., Crystal, R.G., et al. Noggin regulation of bone morphogenetic protein (BMP) 2/7 heterodimer activity in vitro. Bone 39, 61, 2006.
15. Aono, A., Hazama, M., Notoya, K., Taketomi, S., Yamasaki, H., Tsukuda, R., et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 210, 670, 1995.
16. Israel, D.I., Nove, J., Kerns, K.M., Kaufman, R.J., Rosen, V., Cox, K.A., et al. Heterodimeric bone morphogenetic proteins show enhanced activity in vitro and in vivo. Growth Factors 13, 291, 1996.
17. Zhu, W., Rawlins, B.A., Boachie-Adjei, O., Myers, E.R., Arimizu, J., Choi, E., et al. Combined bone morphogenetic protein-2 and-7 gene transfer enhances osteoblastic differentiation and spine fusion in a rodent model. J Bone Miner Res 19, 2021, 2004.
18. Zhao, M., Zhao, Z., Koh, J.T., Jin, T.C., and Franceschi, R.T. Combinatorial gene therapy for bone regeneration: cooperative interactions between adenovirus vectors expressing bone morphogenetic proteins 2, 4, and 7. J Cell Biochem 95, 1, 2005.
19. Sims, N.A., and Gooi, J.H. Bone remodeling: multiple cellular interactions required for coupling of bone formation and resorption. Semin Cell Dev Biol 19, 444, 2008.
20. Irie, K., Alpaslan, C., Takahashi, K., Kondo, Y., Izumi, N., Sakakura, Y., et al. Osteoclast differentiation in ectopic bone formation induced by recombinant human bone morphogenetic protein 2 (rhBMP-2). J Bone Miner Metab 21, 363, 2003.
21. Hunziker, E.B. Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes. Microsc Res Tech 28, 505, 1994.
22. Henriksen, K., Neutzsky-Wulff, A.V., Bonewald, L.F., and Karsdal, M.A. Local communication on and within bone controls bone remodeling. Bone 44, 1026, 2009.
23. Zheng, Y., Wu, G., Zhao, J., Wang, L., Sun, P., and Gu, Z. rhBMP2/7 heterodimer: an osteoblastogenesis inducer of not higher potency but lower effective concentration compared with rhBMP2 and rhBMP7 homodimers. Tissue Eng Part A 16, 879, 2010.
24. Martin, T.J., and Udagawa, N. Hormonal regulation of osteoclast function. Trends Endocrinol Metab 9, 6, 1998.
25. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S., et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesisinhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95, 3597, 1998.
26. Lacey, D.L., Timms, E., Tan, H.L., Kelley, M.J., Dunstan, C.R., Burgess, T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93, 165, 1998.
27. Matsuo, K. Cross-talk among bone cells. Curr Opin Nephrol Hypertens 18, 292, 2009.
28. Kanatani, M., Sugimoto, T., Kaji, H., Kobayashi, T., Nishiyama K., Fukase, M., et al. Stimulatory effect of bone morphogenetic protein-2 on osteoclast-like cell formation and bone-resorbing activity. J Bone Miner Res 10, 1681, 1995.
29. Kaneko, H., Arakawa, T., Mano, H., Kaneda, T., Ogasawara, A., Nakagawa, M., et al. Direct stimulation of osteoclastic bone resorption by bone morphogenetic protein (BMP)-2 and expression of BMP receptors in mature osteoclasts. Bone 27, 479, 2000.
30. Itoh, K., Udagawa, N., Katagiri, T., Iemura, S., Ueno, N., Yasuda, H., et al. Bone morphogenetic protein 2 stimulates osteoclast differentiation and survival supported by receptor activator of nuclear factor-kappaB ligand. Endocrinology 142, 3656, 2001.
31. Xu, J., Li, X., Lian, J.B., Ayers, D.C., and Song, J. Sustained and localized in vitro release of BMP-2/7, RANKL, and tetracycline from FlexBone, an elastomeric osteoconductive bone substitute. J Orthop Res 27, 1306, 2009.
32. Rahman, M.M., Bhattacharya, A., and Fernandes, G. Conjugated linoleic acid inhibits osteoclast differentiation of RAW264.7 cells by modulating RANKL signaling. J Lipid Res 47, 1739, 2006.
33. Xiao, X.H., Liao, E.Y., Zhou, H.D., Dai, R.C., Yuan, L.Q., and Wu, X.P. Ascorbic acid inhibits osteoclastogenesis of RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand (RANKL) in vitro. J Endocrinol Invest 28, 253, 2005.
34. Horii, A., Wang, X., Gelain, F., and Zhang, S. Biological designer self-assembling Peptide nanofiber scaffolds significantly enhance osteoblast proliferation, differentiation and 3-D migration. PLoS One 2, e190, 2007.
35. Gundersen, H.J., and Jensen, E.B. Stereological estimation of the volume-weighted mean volume of arbitrary particles observed on random sections. J Microsc 138, 127, 1985.
36. Matsuo, K., and Irie, N. Osteoclast-osteoblast communication. Arch Biochem Biophys 473, 201, 2008.
37. Wildemann, B., Kadow-Romacker, A., Lubberstedt, M., Raschke, M., Haas, N.P., and Schmidmaier, G. Differences in the fusion and resorption activity of human osteoclasts after stimulation with different growth factors released from a polylactide carrier. Calcif Tissue Int 76, 50, 2005.
38. Makihira, S., Mine, Y., Kosaka, E., and Nikawa, H. Titanium surface roughness accelerates RANKL-dependent differentiation in the osteoclast precursor cell line, RAW264.7. Dent Mater J 26, 739, 2007.
39. Mizoguchi, T., Muto, A., Udagawa, N., Arai, A., Yamashita, T., Hosoya, A., et al. Identification of cell cycle-arrested quiescent osteoclast precursors in vivo. J Cell Biol 184, 541, 2009.
40. Ishii, M., and Saeki, Y. Osteoclast cell fusion: mechanisms and molecules. Mod Rheumatol 18, 220, 2008.
41. Lind, M., Eriksen, E.F., and Bunger, C. Bone morphogenetic protein-2 but not bone morphogenetic protein-4 and-6 stimulates chemotactic migration of human osteoblasts, human marrow osteoblasts, and U2-OS cells. Bone 18, 53, 1996.
42. Fiedler, J., Roderer, G., Gunther, K.P., and Brenner, R.E. BMP-2, BMP-4, and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem 87, 305, 2002.
43. Hou, C.H., Hsiao, Y.C., Fong, Y.C., and Tang, C.H. Bone morphogenetic protein-2 enhances the motility of chondrosarcoma cells via activation of matrix metalloproteinase-13. Bone 44, 233, 2009.
44. Sampath, T.K., Coughlin, J.E., Whetstone, R.M., Banach, D., Corbett, C., Ridge, R.J., et al. Bovine osteogenic protein is composed of dimers of OP-1 and BMP-2A, two members of the transforming growth factor-beta superfamily. J Biol Chem 265, 13198, 1990.
45. Solloway, M.J., and Robertson, E.J. Early embryonic lethality in Bmp5;Bmp7 double mutant mice suggests functional redundancy within the 60A subgroup. Development 126, 1753, 1999.
46. Katagiri, T., Boorla, S., Frendo, J.L., Hogan, B.L.M., and Karsenty, G. Skeletal abnormalities in doubly heterozygous Bmp4 and Bmp7 mice. Developmental Genetics 22, 340, 1998.
47. Lyons, K.M., Hogan, B.L., and Robertson, E.J. Colocalization of BMP 7 and BMP 2 RNAs suggests that these factors cooperatively mediate tissue interactions during murine development. Mech Dev 50, 71, 1995.
48. Martin, T.J., and Sims, N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11, 76, 2005.
49. Wang, J., Zheng, Y., Zhao, J., Liu, T., Gao, L., Gu, Z., et al. Low-dose rhBMP2/7 heterodimer to reconstruct periimplant bone defects: a micro-CT evaluation. J Clin Periodontol 39, 98, 2012.
50. Allendorph, G.P., Isaacs, M.J., Kawakami, Y., Izpisua Belmonte, J.C., and Choe, S. BMP-3 and BMP-6 structures illuminate the nature of binding specificity with receptors. Biochemistry 46, 12238, 2007.
51. Isaacs, M.J., Kawakami, Y., Allendorph, G.P., Yoon, B.H., Belmonte, J.C., and Choe, S. Bone morphogenetic protein-2 and-6 heterodimer illustrates the nature of ligand-receptor assembly. Mol Endocrinol 24, 1469, 2010.
52. Little, S.C., and Mullins, M.C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 11, 637, 2009.